The Role of Vitamin D in Cancer Prevention and Treatment

Overview

Journal Endocrinol Metab Clin North Am

Publisher Elsevier

Specialty Endocrinology

Date 2010 Jun 1

PMID 20511060

Citations 78

Authors

Aruna V Krishnan

Donald L Trump

Candace S Johnson

David Feldman

Affiliations

Soon will be listed here.

Abstract

Calcitriol (1,25-dihydroxyvitamin D(3)), the hormonally active form of vitamin D, exerts growth inhibitory and prodifferentiating effects on many malignant cells and retards tumor growth in animal models. Calcitriol is being evaluated as an anticancer agent in several human cancers. The mechanisms underlying the anticancer effects of calcitriol include inhibition of cell proliferation, stimulation of apoptosis, suppression of inflammation, and inhibition of tumor angiogenesis, invasion, and metastasis. This review discusses some of the molecular pathways mediating these anticancer actions of calcitriol and the preclinical data in cell culture and animal models. The clinical trials evaluating the use of calcitriol and its analogues in the treatment of patients with cancer are described. The reasons for the lack of impressive beneficial effects in clinical trials compared with the substantial efficacy seen in preclinical models are discussed.

Citing Articles

Targeted Drug Screening Leveraging Senescence-Induced T-Cell Exhaustion Signatures in Hepatocellular Carcinoma.

Qi Q, Pang J, Chen Y, Tang Y, Wang H, Gul S Int J Mol Sci. 2024; 25(20).

PMID: 39457014 PMC: 11508728. DOI: 10.3390/ijms252011232.

A real-world study of active vitamin D as a prognostic marker in patients with sarcoma.

Zhang L, Li W, Wang X, Yu S, Zhuang R, Zhou Y Discov Oncol. 2024; 15(1):384.

PMID: 39207640 PMC: 11362410. DOI: 10.1007/s12672-024-01152-4.

The Impact of Vitamin D and Its Dietary Supplementation in Breast Cancer Prevention: An Integrative Review.

Torres A, Cameselle C, Otero P, Simal-Gandara J Nutrients. 2024; 16(5).

PMID: 38474702 PMC: 10934904. DOI: 10.3390/nu16050573.

Emerging perspectives: unraveling the anticancer potential of vitamin D.

Wakle K, Mokale S, Sakle N Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2877-2933.

PMID: 37994947 DOI: 10.1007/s00210-023-02819-5.

A Systematic Review Assessing the Impact of Vitamin D Levels on Adult Patients with Lymphoid Malignancies.

Potre C, Borsi E, Potre O, Ionita I, Samfireag M, Costachescu D Curr Oncol. 2023; 30(4):4351-4364.

PMID: 37185444 PMC: 10137018. DOI: 10.3390/curroncol30040331.

References

Srinivas S, Feldman D . A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009; 29(9):3605-10. View

Gulliford T, English J, Colston K, Menday P, Moller S, Coombes R . A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer. 1998; 78(1):6-13. PMC: 2062933. DOI: 10.1038/bjc.1998.434. View

Gombart A, Luong Q, Koeffler H . Vitamin D compounds: activity against microbes and cancer. Anticancer Res. 2006; 26(4A):2531-42. View

Ng K, Meyerhardt J, Wu K, Feskanich D, Hollis B, Giovannucci E . Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008; 26(18):2984-91. DOI: 10.1200/JCO.2007.15.1027. View

Herszenyi L, Miheller P, Tulassay Z . Carcinogenesis in inflammatory bowel disease. Dig Dis. 2007; 25(3):267-9. DOI: 10.1159/000103898. View

Gonzalez-Sancho J, Larriba M, Ordonez-Moran P, Palmer H, Munoz A . Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Anticancer Res. 2006; 26(4A):2669-81. View

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

Mantovani A, Pierotti M . Cancer and inflammation: a complex relationship. Cancer Lett. 2008; 267(2):180-1. DOI: 10.1016/j.canlet.2008.05.003. View

Park W, Seol J, Kim E, Hyun J, Jung C, Lee C . Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol. 2000; 109(3):576-83. DOI: 10.1046/j.1365-2141.2000.02046.x. View

10.

Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia S . Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res. 2005; 11(1):323-8. View

11.

Chung I, Han G, Seshadri M, Gillard B, Yu W, Foster B . Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res. 2009; 69(3):967-75. PMC: 2752059. DOI: 10.1158/0008-5472.CAN-08-2307. View

12.

Sun J, Kong J, Duan Y, Szeto F, Liao A, Madara J . Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab. 2006; 291(2):E315-22. DOI: 10.1152/ajpendo.00590.2005. View

13.

Peng L, J Malloy P, Feldman D . Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol. 2004; 18(5):1109-19. DOI: 10.1210/me.2003-0344. View

14.

Koli K, Keski-Oja J . 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000; 11(4):221-9. View

15.

Yu X, Bellido T, Manolagas S . Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1995; 92(24):10990-4. PMC: 40556. DOI: 10.1073/pnas.92.24.10990. View

16.

Moreno J, Krishnan A, Swami S, Nonn L, Peehl D, Feldman D . Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005; 65(17):7917-25. DOI: 10.1158/0008-5472.CAN-05-1435. View

17.

Nonn L, Peng L, Feldman D, Peehl D . Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006; 66(8):4516-24. DOI: 10.1158/0008-5472.CAN-05-3796. View

18.

Ly L, Zhao X, Holloway L, Feldman D . Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999; 140(5):2071-6. DOI: 10.1210/endo.140.5.6698. View

19.

Gocek E, Studzinski G . Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci. 2009; 46(4):190-209. PMC: 2820234. DOI: 10.1080/10408360902982128. View

20.

Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H . Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther. 2009; 30(2):113-25. DOI: 10.1111/j.1365-2036.2009.04022.x. View